SynthesisClinical cardiology2017
Cardiovascular safety of NSAIDs: Additional insights after PRECISION and point of view.
Synthesis in Clinical cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Non-steroidal anti-inflammatory drugs for acute low back pain.The Cochrane database of systematic reviews · 2020Pooled it
- Cardiovascular safety of NSAIDs: Additional insights after PRECISION and point of view.Clinical cardiology · 2017Pooled it
- N-Doped Carbon Quantum Dots From Bauhinia purpurea With Anti-Inflammatory and Wound-Healing Properties.Chemistry & biodiversity · 2026Article
- Balancing Pain Relief and Safety: Gastrointestinal and Cardiovascular Risk Assessment in Nonsteroidal Anti-Inflammatory Drug Users and the Role of Gastroprotective Co-Therapy.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Consensus statement on chronic pain treatment in cancer survivors.Journal of anesthesia · 2025Review
- Celecoxib in oncology: targeting the COX-2/PGEFrontiers in pharmacology · 2025Review
- Cardio-rheumatology: the cardiovascular, pharmacological, and surgical risks associated with rheumatological diseases in women.Canadian journal of physiology and pharmacology · 2024Review
- Insights from pharmacovigilance and pharmacodynamics on cardiovascular safety signals of NSAIDs.Frontiers in pharmacology · 2024Article
- Evaluating the Efficacy of ChatGPT in Navigating the Spanish Medical Residency Entrance Examination (MIR): Promising Horizons for AI in Clinical Medicine.Clinics and practice · 2023Article
- Challenges and Opportunities for Celecoxib Repurposing.Pharmaceutical research · 2023Review
- The Safety of Celecoxib as an Acute Treatment for Migraine: A Narrative Review.Pain and therapy · 2023Review
- Celecoxib for Mood Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of clinical medicine · 2023Review
- Assessment and nonsurgical management of low back pain: a narrative review.The Korean journal of internal medicine · 2023Review
- Multimodal Analgesia in the Aesthetic Plastic Surgery: Concepts and Strategies.Plastic and reconstructive surgery. Global open · 2022Article
- Pharmacological modulation of prostaglandin EPhysiological reports · 2022Article
- NSAIDs and Cancer Resolution: New Paradigms beyond Cyclooxygenase.International journal of molecular sciences · 2022Review
- Integrated Serum Metabolomics and Network Pharmacology to Reveal the Interventional Effects of Quzhi Decoction against Osteoarthritis Pain.International journal of analytical chemistry · 2022Article
- Ibuprofen use is associated with reduced C-reactive protein and interleukin-6 levels in chronic spinal cord injury.The journal of spinal cord medicine · 2022Article
- Exploring the causality between ankylosing spondylitis and atrial fibrillation: A two-sample Mendelian randomization study.Frontiers in genetics · 2022Article
- Pharmacological Treatment for Acute Traumatic Musculoskeletal Pain in Athletes.Medicina (Kaunas, Lithuania) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing numbers of patients with arthritis use nonsteroidal anti-inflammatory drugs (NSAIDs), some for long periods. The relative cardiovascular safety of NSAID use is of considerable concern, particularly among patients with or at risk of cardiovascular disease. Until recently, the evidence base was limited to older trials with small sample sizes. The large-scale Prospective Randomized Evaluation of Celecoxib Integrated Safety vs Ibuprofen or Naproxen (PRECISION) trial and a recent Bayesian meta-analysis of individual patient data in nearly a half-million patients were undertaken to address some of the existing gaps in knowledge relative to the cardiovascular safety of NSAID use. We reviewed the results, strengths, and limitations of PRECISION. We believe that the results of the meta-analysis will further assist clinicians in decision-making for management of patients with osteoarthritis. The totality of evidence would support avoidance of NSAID use, if possible, in patients with or at high risk for cardiovascular disease. If used, the shortest-duration and lowest effective NSAID doses should be chosen, given the evidence that risk is duration- and dose-dependent. We also provide a brief discussion of the mechanism of action of NSAIDs, along with discussion of existing guidelines and the recent meta-analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.